Zivo Bioscience, Inc. to Participate in the Global AgTech Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on October 14, 2021 at 10 A.M. EDT
07 October 2021 - 1:09AM
Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) (“ZIVO” and the
“Company”), a biotech/agtech R&D company engaged in the
development and commercialization of therapeutic, medicinal and
nutritional product candidates originally derived from proprietary
algal cultures, announced today that Company CEO Andrew A. Dahl has
been invited to present at the Global AgTech Virtual Conference,
presented by Maxim Group LLC and hosted by M-Vest, on October 14,
2021 at 10 a.m. EDT.
Andrew A. Dahl will be presenting during the
panel titled “The Health and Wellness Panel”.
The event will consist of four virtual panels
with executive management from multiple companies in the AgTech
sector and of keynote speaker Ambassador Kip E. Tom, the Chief
Executive Officer of Leesburg-based Tom Farms, which grows corn,
soybeans, and seed corn in seven northern Indiana counties and is
among Indiana's largest farming operations.
The panel discussions will be moderated by
Anthony Vendetti, Maxim’s Executive Director of Research &
Senior Analyst.
This conference will be live on M-Vest. To
attend, just sign up to become an M-Vest member.
Click Here to Reserve your seat
About Zivo Bioscience, Inc.Zivo
Bioscience, Inc. (NASDAQ: ZIVO) is a Michigan-based biotech/agtech
company engaged in the investigation of the health and nutritional
benefits of bioactive compounds derived from its proprietary algal
cultures, and the development of natural bioactive compounds for
use as dietary supplements and food ingredients, as well as
biologically derived and synthetic candidates for medicinal and
pharmaceutical applications in humans and animals, specifically
focused on the general benefits of autoimmune and inflammatory
response modulation. Visit zivobioscience.com to learn more.
Forward Looking
StatementsExcept for any historical information, the
matters discussed herein contain forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Although ZIVO
believes that we have a reasonable basis for each forward-looking
statement, we caution you that these statements are based on a
combination of facts and factors currently known by us and our
expectations of the future, about which we cannot be certain. Our
actual future results may be materially different from what we
expect due to factors largely outside our control, including risks
that our strategic partnerships may not facilitate the
commercialization or market acceptance of our products; risks that
our products may not be ready for commercialization in a timely
manner or at all; risks that our products will not perform as
expected based on results of our pre-clinical and clinical trials;
our ability to raise additional funds; uncertainties inherent in
the development process of our products; changes in regulatory
requirements or decisions of regulatory authorities; the size and
growth potential of the markets for our products; the results of
clinical trials, our ability to protect our intellectual property
rights and other risks, uncertainties and assumptions, including
those described under the heading “Risk Factors” in our filings
with the Securities and Exchange Commission. These forward–looking
statements speak only as of the date hereof and ZIVO undertakes no
obligation to revise or update any forward–looking statements for
any reason, even if new information becomes available in the
future.
Contacts:Investor
RelationsCORE
IR516-222-2560Investor@zivobioscience.com
MediaCORE IRJules
Abraham917-885-7378julesa@coreir.com
Source: Zivo Bioscience, Inc.
Zivo Bioscience (NASDAQ:ZIVOW)
Historical Stock Chart
From Apr 2024 to May 2024
Zivo Bioscience (NASDAQ:ZIVOW)
Historical Stock Chart
From May 2023 to May 2024